The HPV-DNA molecular test has become the gold standard in cervical cancer screening. Understand the global evolution, the advance of self-collection and the role of specialized laboratories in Brazil.
In recent years, the HPV-DNA test has become one of the main advances in cervical cancer screening thanks to its high sensitivity. Adopted as a primary test by several countries and recommended by the WHO, it is one of the most relevant milestones in the modernization of prevention programs.
Within the international movement to modernize screening, the HPV-DNA molecular test has established itself as the gold standard for its high sensitivity and its ability to identify oncogenic risk directly.
Building on that established base, some countries began evaluating strategies to broaden access to the test, self-collection among them. In 2024, the FDA authorized self-collection for specific HPV-DNA tests, recognizing that these methods can be safely processed when the sample is collected by the patient in a clinical setting.
In December 2025, the American Cancer Society (ACS) updated its recommendations and recognized self-collection as a valid alternative within HPV-DNA-based screening. These international advances complement the global consolidation of molecular testing as the main screening tool.
In Brazil, the update process has also intensified. The Ministry of Health has been strengthening guidelines that position HPV-DNA as the primary screening test for cervical cancer, with progressive expansion in the public health system and growing adoption of the molecular approach in prevention programs.
In this context of modernization, the recent approval of self-collection in the country is an additional development: a tool capable of expanding coverage and reducing access barriers, always supported by the larger guideline of transitioning to HPV-DNA-based screening as the core of public policy.
This combination — full adoption of HPV-DNA and the gradual introduction of self-collection models — marks Brazil's current period, entering 2026 with a robust agenda for modernizing screening and expanding molecular diagnostics.
In this article we detail what these advances represent, how they affect the Brazilian health system, why HPV-DNA became the global standard, and the role of specialized laboratories such as Base Científica in the safe, qualified expansion of this technology.
Why HPV-DNA returned to the center of global discussions
Molecular diagnostics has consolidated globally as a central axis of health prevention strategies. In this context, the HPV-DNA test, which directly detects the virus's genetic material, became the international standard in cervical cancer screening programs, supported by robust evidence of greater sensitivity and efficiency compared with traditional cytology.
The topic gained new momentum with important updates across health systems. In 2024, the FDA authorized self-collection for specific HPV-DNA tests, validating the model in clinical settings. In December 2025, the ACS updated its recommendations and formally recognized self-collection as an acceptable alternative within HPV-DNA-based screening, reinforcing the trend of expanding access without losing diagnostic quality.
These international movements broadened the debate on diagnostic inclusion, digital health and more accessible care models, especially in countries with logistical challenges or territorial inequalities. In parallel, the WHO continues to recommend HPV-DNA as the primary screening method, highlighting its greater sensitivity and the possibility of longer intervals between tests, a crucial aspect for realities similar to Brazil's.
What the ACS update on self-collection for HPV-DNA means
The update published by the ACS in December 2025 marks a significant advance in HPV screening — not because it is the first recognition of self-collection, since the FDA had approved self-collection solutions in 2024, but because it formally incorporates the method into highly influential guidelines.
While the FDA approval validated the safety and efficacy of specific devices, the ACS decision broadens the impact by guiding clinical practice, public policy and screening programs on a global scale.
With the new recommendation, self-collection is recognized as a safe and effective alternative for women to collect their own sample at home, following standardized instructions and sending the material to accredited laboratories. The test remains the same high-precision molecular assay, but the collection method reduces access barriers.
This update means higher screening adherence, less need to travel to health units, expansion of large-scale campaigns and programs, and greater reach in populations with cultural or geographic barriers.
The change was received very positively by public health institutions and specialists, who see it as an important step toward a new phase of cancer screening.
How Brazil is advancing in HPV-DNA screening
Brazil has been advancing in a structured way in adopting the HPV-DNA molecular test in the public health system. The technology was officially incorporated in March 2024, and the new national guidelines, approved by Conitec in February 2025, established HPV-DNA as the primary screening method.
In August 2025, the Ministry of Health marked the start of practical implementation in the states, with gradual expansion of collection and processing in public units. In the same month, the country also approved self-collection as a complementary strategy, expanding access and aligning Brazil with international screening recommendations.
This progressive implementation represents a strategic shift in the Brazilian prevention model, especially by reducing access barriers and modernizing population-based screening. Recent technical materials produced by INCA reinforce this transition by guiding managers on workflows, sampling, triage and integration of molecular testing into regional programs.
With these advances, Brazil moves closer to global best practices and reinforces its public commitment to eliminating cervical cancer as a health problem, an objective defended by the Ministry of Health in international agendas.
Base Científica and the role of CROs in the future of molecular screening
With the global advance of molecular methodologies and growing demand for HPV-DNA, a challenge emerges: the country needs technically prepared laboratories with the capacity to scale.
In the Brazilian context, many municipalities and clinics lack the structure to perform highly complex molecular analyses. This is where CROs and specialized laboratories such as Base Científica come in, acting as strategic partners with robust, reliable services.
The main reasons for this need include the sharp increase in demand for HPV-DNA, the need for national standardization to ensure quality, the capacity to handle high volumes with fast turnaround, advanced sample security and traceability, and constant alignment with regulatory requirements.
The relevance of the B2B model in expanding access to HPV-DNA
In Brazil, the B2B model plays a crucial role in making molecular technologies more accessible. Specialized laboratories can support clinics without molecular biology infrastructure, mid-sized laboratories seeking to expand their portfolio, hospital operations aiming to reduce costs, and health departments looking to expand coverage.
The B2B model enables centralized processing, lower operating costs, faster results and immediate scale without large investments.
Support for the public sector and stronger access to molecular diagnostics
For public health programs, working with laboratories specialized in molecular biology is essential to ensure scalability in regional campaigns, homogeneous result quality, operational workflows compatible with public system routines, analytical capacity for large sample volumes, qualified technical follow-up and methodological standardization at every stage.
This support is fundamental to expanding access to molecular screening, especially in municipalities where laboratory infrastructure is still limited or nonexistent.
That is why Base Científica has also taken part in recent public initiatives aimed at expanding access to molecular diagnostics. During the Outubro Rosa campaign, the laboratory processed the HPV-DNA tests offered free of charge in the municipalities of Sidrolândia, Terenos and Dois Irmãos do Buriti, in Mato Grosso do Sul.
The initiative, promoted by municipal and state governments, brought qualified screening to regions where the population usually has less access to high-sensitivity tests. By processing the samples, Base Científica helped ensure fast, safe and standardized results, reinforcing the role of molecular biology in cervical cancer prevention and showing how technical partnerships strengthen public health policy.
Support for clinics, laboratories and private institutions
Many clinics and laboratories face challenges in adding molecular biology tests to their portfolio, whether due to high infrastructure investment or the need for highly specialized professionals.
To support this growth, Base Científica acts as a partner laboratory, allowing institutions across the country to offer a range of tests, HPV-DNA among them, without building an internal molecular unit.
Our support includes complete processing with precision and agility, clear and objective reports that integrate into clinical workflows, technical guidance for implementing sample shipping flows, simple integration with the partner institution's system, and scalability for both routine demand and seasonal peaks.
Clinics, hospitals and laboratories can therefore expand their portfolio, diversify services and keep pace with growing demand for high-sensitivity tests without compromising current operations.
Why the global movement around HPV-DNA requires preparation now
The ACS approval is not merely news. It is a trend indicator. The world is moving rapidly toward broader use of HPV-DNA, and countries that anticipate this will achieve more consistent prevention results.
Brazil is going through a moment of regulatory transition and strengthening public policy, which requires preparation from clinics, laboratories and institutions. Those who start structuring workflows and partnerships now will be better positioned for new guidelines.
Key points of attention for clinics, hospitals, health departments and laboratories in the coming years include continued growth in HPV-DNA demand, possible revision of national guidelines, government incentives for broader screening, pressure for scalability and speed, the importance of specialized laboratory partners, and the global trend of including self-testing in regulatory debates.
Qualified partners will be essential
The international landscape and recent policy movements show that HPV-DNA is consolidating as the main test for cervical cancer prevention. The ACS approval of self-testing reinforces a global trend that has already reached Brazil.
To ensure efficient, safe and broadly covered screening, public and private institutions will need prepared laboratories capable of offering scalability, precision and technical support, especially in a country of continental dimensions.
Base Científica positions itself as a strategic partner for those seeking to expand or structure their HPV-DNA offering, with solidity, technical responsibility and an absolute focus on quality.
Does the ACS influence decisions in Brazil?
Not directly, since the ACS is not a regulatory agency, but its guidelines strongly influence scientific institutions, policymakers, medical societies and technology suppliers in several countries, including Brazil.
When a highly prestigious organization such as the ACS updates its recommendations and recognizes methods like self-collection for HPV-DNA, it tends to generate movement in Brazil, leading institutions and laboratories to review internal processes, update portfolios and screening workflows, reassess technologies and seek alignment with evidence-based international best practices.
This influence occurs because ACS guidelines usually serve as a global scientific reference, affecting technical and strategic decisions even outside the United States.
If Brazil already offers HPV-DNA in the public system, why does the private sector need to update?
Because when the public system adopts something, it sets a national trend. Clinics, hospitals and laboratories that do not keep up fall behind the public standard, and this affects competitiveness, the ability to attract health plans and perceived quality.
Can laboratories without in-house molecular analysis keep up with this change?
Yes, and this is one of the reasons for the growth of outsourcing to laboratories specialized in molecular biology. This strategy modernizes the portfolio without high investment or hiring specialized teams.
What is the main technical challenge for clinics and laboratories adding HPV-DNA to their portfolio?
The biggest challenges are ensuring quality and reproducibility of results, integrating collection and transport flows, standardizing reports for clinical teams and handling variable volumes, especially during campaigns, health-plan contracts or municipal initiatives. That is why many services choose partnerships with laboratories that already have routine, quality control and technical support capacity.
Why are municipalities and state departments expanding HPV-DNA screening initiatives?
Mainly for three reasons: high sensitivity, which reduces loss to follow-up; feasibility in campaigns, since it requires fewer patient return visits; and partnerships with specialized laboratories, which make it possible to handle large volumes on short timelines. This model was used, for example, in recent public initiatives during Outubro Rosa in Mato Grosso do Sul.
What is the role of specialized laboratories in these campaigns?
They ensure fast, standardized processing, quality maintenance even at high volume, technical support for local teams and objective reports that integrate into municipal systems. This support makes campaigns viable in regions with limited structure, without building complex laboratories.
Do these public initiatives affect the private sector?
Yes. When the public sector adopts molecular screening, the private sector sees an immediate increase in demand and a need to update its portfolio. Health plans start looking for laboratories offering HPV-DNA, clinics require more scalability and general laboratories look for specialized partners.
Does outsourcing to a specialized laboratory compromise a service's autonomy?
No. In practice it increases autonomy: it expands the portfolio, provides operational security, allows volumes to scale without risk and reduces fixed investment. The service maintains the relationship with the patient or contracting party; the partner laboratory simply guarantees molecular quality.
Why is it important to discuss this now?
Because the sector is entering a rare phase of convergence: the public system adopting the technology, the FDA reinforcing the method as the gold standard, state campaigns using HPV-DNA, rising demand from clinics and health plans, and the need to expand laboratory capacity. Those who position themselves now — updating portfolios, creating workflows and forming strategic partnerships — will be ahead when molecular screening becomes the dominant standard.
References
FDA and ACS — self-testing and advances in the US: approval of the first at-home cervical cancer self-test (2025); authorization of HPV tests with self-collection in health services (2024); update of the American Cancer Society screening recommendations.
Brazilian public health system — Ministry of Health: national technology for DNA-HPV screening (2025); molecular test offered in the public system (2025); PAHO, national implementation of the DNA-HPV test with international support (2025).
International guidelines: WHO global strategy to eliminate cervical cancer (2020–2023) and new screening and treatment recommendations; INCA epidemiological data on HPV and cervical cancer.